

Table of Contents

INTRODUCTION 	1
1. Cellular senescence	3
1.1 Mechanism of cellular arrest	4
1.2 Hallmarks of senescent cells	6
1.3 Senescence in physiology and disease	11
2. Senolytic therapy	13
2.1 Navitoclax.....	16
2.2 Galactose-modified senolytic pro-drugs.....	19
2.3 Senolytics in clinics.....	21
3. Nanotechnology and nanomedicine	22
3.1 Nanodevices targeting senescent cells.....	24
3.2 Mesoporous silica nanoparticles (MSNs).....	28
3.2.1 Galacto-coated mesoporous silica nanoparticles (GalNPs).....	31
4. Senescence and the heart	32
4.1 Senescence in specific cardiac cell types	34
4.2 Senescence and heart regeneration.....	37
4.3 Senescence in cardiac pathology	39
4.4 Targeting cardiac senescence therapeutically	43
5. Cardiotoxicity of doxorubicin	45
5.1 Doxorubicin-induced senescence	49
OBJECTIVES 	53
MATERIALS AND METHODS 	57
1. Cell culture	59
1.1 Senescence induction.....	59

2. Senescence characterization	60
2.1 β -galactosidase activity assay.....	60
2.2 β -galactosidase determination by flow cytometry.....	60
2.3 Cell cycle assay	61
2.4 Cell proliferation	62
2.5 Clonogenic assay.....	62
2.6 Western blot.....	62
2.7 Ki67 immunofluorescence.....	64
3. Synthesis of nanomaterials	65
3.1 Synthesis of mesoporous silica nanoparticles (MSNs)	65
3.2 Synthesis of loaded MSNs.....	67
3.3 Functionalization of loaded MSNs.....	67
4. Structural characterization of prepared nanoparticles	69
4.1 Powder X-ray diffraction (PXRD)	69
4.2 Transmission electron microscopy (TEM).....	69
4.3 Nitrogen adsorption-desorption (porosimetry).....	70
4.4 Thermogravimetric analysis (TGA)	70
4.5 Dynamic light scattering (DLS) and Zeta Potential (ZP).....	70
4.6 UV-visible and fluorescence spectrophotometry	71
4.7 Cargo release studies <i>in vitro</i>	71
5. Synthesis of Nav-Gal prodrug	72
6. Characterization of Nav-Gal prodrug	72
7. Cellular studies	73
7.1 Cytotoxicity cell studies	73
7.2 Doxorubicin dose-response	73
7.3 Cytotoxic effect of senolytic treatment	74

7.4 Cellular uptake of nanoparticle	75
7.4.1 Cargo release study of GalNP(ICG) by confocal microscopy.....	75
7.4.2 Cargo release study of GalNP(ICG) by flow cytometry.....	76
8. Mouse model	76
8.1 Doxorubicin-induced cardiotoxicity mice model.....	77
8.2 Senolytic treatment study	77
9. Echocardiography	79
10. Tissue collection and processing.....	80
11. Immunofluorescence	81
12. WGA staining.....	82
13. Gene expression analysis.....	82
13.1 RNA isolation.....	82
13.2 RNA quality control	84
13.3 cDNA synthesis	84
13.4 Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)	85
14. Statistical analysis.....	86
RESULTS	89
1. Induction of cellular senescence in HL-1 cardiac myocyte cell line upon doxorubicin treatment.....	91
2. Synthesis of galactan-capped nanoparticles loaded with navitoclax (GalNP(nav)).....	99
3. Galactan-capped nanoparticles loaded with ICG deliver their cargo to senescent HL-1 cells versus non-senescent	105
4. Encapsulated navitoclax improves senolytic activity in senescent cardiac myocytes.....	107

5. Nav-Gal prodrug protects non-senescent cardiomyocyte cells from apoptosis.....	109
6. Doxorubicin induces senescence accumulation in heart tissue and cardiac dysfunction in mice	114
7. Navitoclax-based therapies restore cardiac function in a doxorubicin-induced cardiotoxicity mouse model.....	126
DISCUSSION 	135
1. Validation of senolytic therapy in senescent cardiomyocytes <i>in vitro</i> . 137	
2. Doxorubicin-induced cardiotoxicity correlates with cardiac senescence	140
3. Senolysis therapy alleviates DOX-induced cardiotoxicity	144
CONCLUSIONS	155
REFERENCES 	159